Cytek Biosciences Inc logo

Cytek Biosciences Inc(CTKB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 68 days
PROFIT SINCE LAST BUY
+31.05% ▲
LAST CLOSE
$6.12
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CTKB

11/20/2026: CTKB (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Cytek Biosciences Inc is a life sciences tools company specializing in advanced full-spectrum flow cytometry instrumentation and reagents for biomedical research and clinical markets. The company's primary strength lies in its patented Full Spectrum Profiling technology, which delivers high-parameter single-cell analysis supported by solid gross margins and a cash-rich balance sheet. Its core growth story centers on expanding its installed instrument base and driving recurring reagent and software revenue, alongside a push into regulated clinical diagnostics. However, the company faces risks from ongoing net unprofitability, lumpiness in capital equipment spending, and intense competition from entrenched industry titans. The stock suits growth-oriented investors with high risk tolerance who are willing to monitor execution milestones in clinical market expansion.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitTop-line expansion has slowed down recently, though technological potential in spectral flow keeps long-term growth interest intact.
Momentum investorWeak fitStock price action has experienced extended consolidation periods without consistent upward technical momentum.
Value investorMixed fitThe company trades at reasonable price-to-sales multiples with a strong cash cushion, but lacks current net profitability.
Dividend investorWeak fitCytek pays no dividends and retains all capital to fund ongoing operations and research.
Low-risk investorWeak fitAs a small-cap, unprofitable life sciences tools provider, the stock is subject to high volatility and operational execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap biotechnology and tools equities experience sharp price swings relative to broader market indices.
Valuation riskMediumValuation relies heavily on future growth realization since current earnings are negative.
Competition risk (large medical device incumbents)HighWell-capitalized market titans possess deeper bundling capabilities and extensive global sales channels.
Business qualityMediumProprietary FSP technology and healthy gross margins indicate solid underlying product value despite ongoing unprofitability.
Dividend incomeLow / noneThe company offers zero dividend yield, making it entirely unsuitable for income-focused portfolios.
Execution riskMedium / highSuccessful translation of research-use instruments into regulated clinical markets requires flawless operational execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 826.55M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 1.3M shares
Beta 1.14
52 Weeks Range 3.31 - 6.38
Updated Date 11/20/2026
52 Weeks Range 3.31 - 6.38
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.63

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Medical Devices

BUY participation
33.3%
Active BUY / eligible
2 / 6
30-Day BUY Count Change
+2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -19.47%
Avg. Invested days 32
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CTKB receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
CTKB has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-1005.3%), weak cash generation (FCF margin -4.4%), moderate revenue growth (+0.5%).

Financial Health Rating

★★★★★
CTKB's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 68.1%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CTKB's strongest growth driver at +0.5% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-1005.3%, negative) and free-cash-flow growth (-140.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 65.5% and approximately 80.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 8.42% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.32%
Millennium Management LLC 7.14%
Boston Partners Global Investors, Inc 5.86%
Hillhouse Capital Advisors, Ltd. 5.09%
Topline Capital Management LLC 4.80%

Unit Economics (Per $1K Revenue)

★★★★★
CTKB generates approximately $518 of gross profit, $-200 of operating income, and $-44 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -122.98% (Tax Credit)

Quantitative Style Profile

★★★★★
CTKB has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Cell Analysis InstrumentsSales of flagship flow cytometry hardware systems including Aurora, Northern Lights, and Aurora Evo instruments.This is the primary upfront revenue engine, though capital sales can fluctuate with research budget cycles.
Reagents, Consumables & ServicesProprietary assay kits, reagents, service contracts, and software subscriptions like SpectroFlo and Cytek Cloud.Provides a high-margin recurring revenue stream that scales as the installed base of instruments grows.
Geographic OperationsDirect and distributor-led sales across North America, Europe, China, and the broader Asia-Pacific region.Geographic diversification helps buffer regional funding fluctuations in academic and biopharma sectors.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 370.37
Enterprise Value 595.34M
Price to Sales(TTM) 3.98
Enterprise Value 595.34M
Price to Sales(TTM) 3.98
Enterprise Value to Revenue 2.62
Enterprise Value to EBITDA 222.69
Shares Outstanding 130.78M
Shares Floating 105.80M
Shares Outstanding 130.78M
Shares Floating 105.80M
Percent Insiders 8.42
Percent Institutions 65.53

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.